Esmya (ulipristal acetate): suspension of the licence due to risk of serious liver injury

The licence for Esmya has been suspended to protect public health while a safety review is conducted following a further case of liver injury requiring transplant. Patients currently taking Esmya for uterine fibroids should be advised to stop their treatment immediately.

Medicines and Healthcare products Regulatory Agency